Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial

BACKGROUND: A profound need remains to develop further therapeutics for treatment of those hospitalized with COVID-19. Based on data implicating the type 2 cytokine interleukin (IL)-13 as a significant factor leading to critical COVID-19, this trial was designed to assess dupilumab, a monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasson, Jennifer, Donlan, Alexandra N., Ma, Jennie Z., Haughey, Heather M., Coleman, Rachael, Nayak, Uma, Mathers, Amy J., Laverdure, Sylvain, Dewar, Robin, Jackson, Patrick E. H., Heysell, Scott K., Sturek, Jeffrey M., Petri, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996634/
https://www.ncbi.nlm.nih.gov/pubmed/35411349
http://dx.doi.org/10.1101/2022.03.30.22273194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996634/
https://www.ncbi.nlm.nih.gov/pubmed/35411349
http://dx.doi.org/10.1101/2022.03.30.22273194

Ejemplares similares